CD22 and neoplasm: According to the WHO definition, CLL/SLL cells typically co-express CD5 and CD23, and flow cytometry reveals that tumor cells express dim surface IgM/IgD, CD20, CD22, CD5, CD19, CD79a, CD23, CD43, and CD11c (weak).